BioAge Labs, Inc. today filed a preliminary prospectus supplement with the SEC to offer up to $75.0 million of its common shares and has granted underwriters a 30-day option to purchase an additional $11.25 million. Goldman Sachs, Piper Sandler and Citigroup are acting as joint book-running managers. The company intends to use net proceeds, together with existing cash and marketable securities, to advance clinical and process development of BGE-102, further its NLRP3 and APJ programs, support manufacturing scale-up, fund working capital and capital expenditures, reduce indebtedness and for general corporate purposes. The offering will be made pursuant to a shelf registration statement that became effective on November 25, 2025, and the timing, size and terms remain subject to market conditions and SEC review.

BioAge has expanded its lead candidate BGE-102 into ophthalmology, planning a randomized Phase 1b/2a proof-of-concept study in diabetic macular edema patients beginning mid-2026. The trial will evaluate three arms—BGE-102 monotherapy, combination with a VEGF inhibitor, and control—with primary endpoint of percent change in intraocular IL-6. Exploratory endpoints include best-corrected visual acuity, central subfield thickness and biomarker panels. Results are expected mid-2027, running alongside a Phase 2a cardiovascular risk study with topline data anticipated in the second half of 2026. In preclinical DME models, oral BGE-102 achieved near-complete protection against vascular leakage, preserved up to 90% of microvascular integrity, and reduced retinal lipofuscin accumulation by approximately 80%.